In a recent broadcast, journalist Rachel Maddow spotlighted an unexpected health success story—former President Donald Trump’s improved physical condition as reflected in his latest medical report. Trump reportedly lost 20 pounds and saw a dramatic drop in his LDL cholesterol, shifting from obese to overweight. This transformation, according to former FDA Commissioner Dr. David Kessler, is likely the result of intensive lipid-lowering therapy—a drug regimen commonly used to prevent cardiac disease. While Trump has not confirmed using GLP-1 weight loss drugs like Ozempic or Wegovy, the speculation remains.

However, Maddow argues that this personal health victory is overshadowed by a troubling contradiction: while Trump benefits from top-tier medical care and scientific advancements, his administration has actively undermined public access to these same resources. Under his leadership, nearly $2 billion in NIH research grants were slashed, and the FDA suffered severe staffing and operational cuts. Moreover, Trump has reversed a Biden-era proposal that would have allowed Medicare to cover GLP-1 weight loss drugs—potentially limiting access for millions.

The disparity Maddow highlights is stark. The same public institutions that enabled Trump’s improved health are being dismantled for everyone else. She contends this isn’t just about one man’s medical journey—it’s a policy issue with life-or-death consequences for tens of millions of Americans. Trump’s case shows what’s possible with proper treatment and science-backed care. But without structural support for public health, that success remains a privilege for the few—not a right for all.